<a href="https://laohu8.com/S/LYRA">Lyra Therapeutics</a> Receives Nasdaq Deficiency Notice for Failing to Meet Stockholders' Equity Requirement
Lyra Therapeutics Inc. has announced that it received a Deficiency Letter from The Nasdaq Stock Market LLC on August 20, 2025, indicating that the company's stockholders' equity, as reported in its quarterly report for the period ending June 30, 2025, does not meet the continued listing requirement under Nasdaq Listing Rule 5550(b)(1). The rule mandates a stockholders' equity of at least $2.5 million, while Lyra's equity stands at approximately $1.6 million. This notification does not immediately affect the trading of Lyra's common stock, which will continue to trade under the symbol "LYRA." Lyra has until October 4, 2025, to submit a plan to Nasdaq to regain compliance. If the plan is accepted, Nasdaq may grant an extension of up to 180 calendar days for compliance. There is no assurance the plan will be accepted or that compliance will be achieved within the allotted time frame.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lyra Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-186437), on August 22, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.